Melissa K. Bennett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Melissa K. Bennett has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Briony L. Gliddon
Molecular Therapeutics Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia
1 shared publication - Jason A. Powell
Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia
1 shared publication - John Toubia
Centre for Cancer Biology, an alliance between SA Pathology and the University of South Australia , Adelaide, SA 5000
1 shared publication - Manjun Li
Centre for Cancer Biology University of South Australia and SA Pathology Adelaide South Australia Australia
1 shared publication - Melinda N. Tea
Molecular Therapeutics Laboratory, Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia
1 shared publication - Michael Susithiran Samuel
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia
1 shared publication
Latest Publications
- Open Access
- 5 December 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (2) , 566-570
An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma
Summary: While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib‐resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib‐resistant MM mouse model based on the most well‐characterised syngeneic MM mouse model derived from spontaneous MM‐forming C57BL/KaLwRij mice. Using bortezomib‐resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib‐resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor‐resistant MM.
- 5 December 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (2) , 566-570
Open AccessAn orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma
Summary: While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib‐resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib‐resistant MM mouse model based on the most well‐characterised syngeneic MM mouse model derived from spontaneous MM‐forming C57BL/KaLwRij mice. Using bortezomib‐resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib‐resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor‐resistant MM.